Anti-rheumatic drugs are medications used to treat rheumatic diseases, which are conditions characterized by inflammation, pain, stiffness, and swelling in the joints, muscles, and other connective tissues. Rheumatic diseases encompass a wide range of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and juvenile idiopathic arthritis, among others. The goals of treatment with anti-rheumatic drugs are to reduce inflammation, alleviate symptoms, prevent disease progression, and improve overall quality of life for patients.

The global Anti-Rheumatic Drugs market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Anti-Rheumatic Drugs Industry Forecast” looks at past sales and reviews total world Anti-Rheumatic Drugs sales in 2022, providing a comprehensive analysis by region and market sector of projected Anti-Rheumatic Drugs sales for 2023 through 2029. With Anti-Rheumatic Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Anti-Rheumatic Drugs industry.

This Insight Report provides a comprehensive analysis of the global Anti-Rheumatic Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Anti-Rheumatic Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Anti-Rheumatic Drugs market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Anti-Rheumatic Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Anti-Rheumatic Drugs.

United States market for Anti-Rheumatic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Anti-Rheumatic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Anti-Rheumatic Drugs is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Anti-Rheumatic Drugs players cover Novartis, UCB, AbbVie, Bristol-Myers Squibb, Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Anti-Rheumatic Drugs market by product type, application, key players and key regions and countries.

Segmentation by Type:

• Disease Modifying Anti-rheumatics Drugs (DMARD's)
• Nonsteroidal Anti-inflammatory Drugs (NSAID's)
• Corticosteroids
• Uric Acid Drugs
• Others

Segmentation by Application:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

This report also splits the market by region:

• Americas
  • United States
  • Canada
  • Mexico
  • Brazil
• APAC
  • China
  • Japan
  • Korea
  • Southeast Asia
  • India
  • Australia
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Russia
• Middle East & Africa
  • Egypt
  • South Africa
  • Israel
  • Turkey
  • GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Novartis
• UCB
• AbbVie
• Bristol-Myers Squibb
• Merck
• HEYL Chemisch-pharmazeutische Fabrik
• Roche
• Johnson & Johnson
• Amgen
• Pfizer
• GSK
• Sanofi
• Abbott Laboratories
• Teva Pharmaceutical
• Eli Lilly and Company
• Celltrion
• Astellas Pharma
• Simcere
• Daiichi Sankyo
• Asahi Kasei